Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model.

Biochemical and Biophysical Research Communications
Ken-ichiro FukuchiRobert Lalonde

Abstract

Parenteral immunization of transgenic mouse models of Alzheimer disease (AD) with synthetic amyloid beta-peptide (Abeta) prevented or reduced Abeta deposits and attenuated their memory and learning deficits. A clinical trial of immunization with synthetic Abeta, however, was halted due to brain inflammation, presumably induced by a toxic Abeta, T-cell- and/or Fc-mediated immune response. Another issue relating to such immunizations is that some AD patients may not be able to raise an adequate immune response to Abeta vaccination due to immunological tolerance or age-associated decline. Because peripheral administration of antibodies against Abeta also induced clearance of amyloid plaques in the model mice, injection of humanized Abeta antibodies has been proposed as a possible therapy for AD. By screening a human single-chain antibody (scFv) library for Abeta immunoreactivity, we have isolated a scFv that specifically reacts with oligomeric Abeta as well as amyloid plaques in the brain. The scFv inhibited Abeta amyloid fibril formation and Abeta-mediated cytotoxicity in vitro. We have tested the efficacy of the human scFv in a mouse model of AD (Tg2576 mice). Relative to control mice, injections of the scFv into the brain of Tg...Continue Reading

Citations

Nov 23, 2012·ACS Chemical Neuroscience·Pauline T VelascoWilliam L Klein
Jul 30, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kelly L SudolWilliam J Bowers
Jun 17, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Deborah A RyanWilliam J Bowers
Nov 6, 2009·The Journal of Biological Chemistry·Sharad P AdekarBrian O'Nuallain
Jun 15, 2013·Protein Engineering, Design & Selection : PEDS·R M NisbetS D Nuttall
Nov 14, 2007·Expert Review of Neurotherapeutics·Cheryl A Hawkes, Joanne McLaurin
Nov 24, 2007·Expert Opinion on Biological Therapy·Brian SpencerEliezer Masliah
Jan 26, 2011·Expert Opinion on Biological Therapy·Refik PulMartin Stangel
Nov 19, 2013·The Journal of Pharmacy and Pharmacology·Brígida R PinhoPaula B Andrade
Jan 19, 2007·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Clifford R JackMichael Garwood
Jan 27, 2020·Neurobiology of Disease·Senthilkumar KrishnaswamyEinar M Sigurdsson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Microglia

Microglia are a type of glial cell found throughout the brain and spinal cord. Microglia have been found to be associated with Alzheimer's disease development and progression. Here are the latest discoveries pertaining to Alzheimer's disease and microglia.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.